Biotech Values

[biomaven0]

improvement in bone mets by itself will likely not be an approvable endpoint

I haven't listened to the webcast, but I personally don't see why improvement in bone mets (including reduction in fractures and pain as secondary endpoints) doesn't make a perfectly acceptable primary endpoint. It's objective, measurable and clinically significant. Thus it's not a surrogate endpoint like tumor size, which may or may not be associated with improved survival or clinical benefits.

Peter